계명대학교 의학도서관 Repository

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Metadata Downloads
Author(s)
Young-Hwan AhnHeirim LeeDo Young KimHye Won LeeSu Jong YuYoung Youn ChoJeong Won JangByoung Kuk JangChang Wook KimHee Yeon KimHana ParkHyo Jung ChoBumhee ParkSoon Sun Kim1Jae Youn Cheong
Keimyung Author(s)
Jang, Byoung Kuk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Gut and liver
Issued Date
2021
Volume
15
Issue
3
Keyword
Carcinoma, hepatocellularAntiviral agentsRisk factorsHepatitis C, chronicRecurrence
Abstract
Background/aims:
This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence.

Methods:
A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results.

Results:
Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR, 3.73; p<0.001; HR, 3.34; p<0.001; and HR, 1.74; p=0.006, respectively).

Conclusions:
DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy.
Keimyung Author(s)(Kor)
장병국
Publisher
School of Medicine (의과대학)
Citation
Young-Hwan Ahn et al. (2021). Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut and liver, 15(3), 410–419. doi: 10.5009/gnl20151
Type
Article
ISSN
2005-1212
Source
http://www.gutnliver.org/journal/view.html?doi=10.5009/gnl20151
DOI
10.5009/gnl20151
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43548
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.